Skip to main content
Article thumbnail
Location of Repository

Aurora kinase inhibitors: current status and outlook

By Vassilios eBavetsias and Spiros eLinardopoulos

Abstract

The Aurora kinase family comprises of cell cycle-regulated serine/threonine kinases important for mitosis. Their activity and protein expression are cell cycle regulated, peaking during mitosis to orchestrate important mitotic processes including centrosome maturation, chromosome alignment, chromosome segregation and cytokinesis. In humans, the Aurora kinase family consists of three members; Aurora-A, Aurora-B and Aurora-C, that each share a conserved C-terminal catalytic domain but differ in their sub-cellular localization, substrate specificity and function during mitosis. In addition, Aurora-A and Aurora-B have been found to be overexpressed in a wide variety of human tumors. These observations led to a number of programs among academic and pharmaceutical organizations to discovering small molecule Aurora kinase inhibitors as anti-cancer drugs. This review will summarize the known Aurora kinase inhibitors currently in the clinic and the current and future directions

Topics: Hematologic Diseases, Neuroblastoma, small molecules, Aurora kinase, kinase inhibitors, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Publisher: Frontiers Media S.A.
Year: 2015
DOI identifier: 10.3389/fonc.2015.00278
OAI identifier: oai:doaj.org/article:41fbebd52f934cf98911a67ef55585cb
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://doaj.org/toc/2234-943X (external link)
  • http://journal.frontiersin.org... (external link)
  • https://doaj.org/article/41fbe... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.